Policy / Pricing SCOTUS won’t hear pharma’s IRA complaints PharmaphorumThe US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare’s drug pricing negotiation powers. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck ADC, licensed from China, hits mark in first big global trialNext: Sanofi says drug for rare disease AATD tops standard care Related Stories Policy / Pricing Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019 pharminent May 18, 2026 Policy / Pricing Biotech leaders pitch Pazdur as next FDA chief pharminent May 14, 2026 Policy / Pricing Joint MHRA/NICE pathway ‘benefits industry over patients’ pharminent May 14, 2026
